NEO-2734 is under clinical development by Epigene Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NEO-2734’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NEO-2734 overview

NEO-2734 is under development for the treatment of solid tumor, acute myelocytic leukemia, breast cancer, colon cancer, glioblastoma, prostate cancer, lung cancer, lymphoma, neuroblastoma, ovarian cancer, melanoma, mesothelioma, relapse or refractory castration-resistant prostate cancer (CRPC), NUT midline carcinoma   and pancreatic cancer. It is administered orally. The drug candidate acts by targeting BET and CBP/P300. Brd4 is a bromodomain domain-4 protein which functions as a epigenetic modulator. The drug candidate is developed based on platform which consists of chemoinformatic and structure-based drug discovery.

Epigene Therapeutics overview

Epigene Therapeutics is a biotechnology company that develops small molecule-based therapeutics to treat cancer. The company is headquartered in Canada.

For a complete picture of NEO-2734’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.